Matinas Biopharma (MTNB) Competitors

Synergy CHC (NASDAQ:SNYR) and Matinas Biopharma (NYSE:MTNB) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Do insiders and institutionals hold more shares of SNYR or MTNB?

11.8% of Matinas Biopharma shares are owned by institutional investors. 56.6% of Synergy CHC shares are owned by company insiders. Comparatively, 4.6% of Matinas Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has preferable valuation & earnings, SNYR or MTNB?

Synergy CHC has higher revenue and earnings than Matinas Biopharma. Matinas Biopharma is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$33.70M	0.82	$2.12M	$0.38	7.74
Matinas Biopharma	N/A	N/A	-$22.94M	-$3.89	-0.55

Is SNYR or MTNB more profitable?

Synergy CHC has a net margin of 10.02% compared to Matinas Biopharma's net margin of 0.00%. Synergy CHC's return on equity of -18.56% beat Matinas Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	10.02%	-18.56%	20.28%
Matinas Biopharma	N/A	-123.06%	-94.28%

Do analysts rate SNYR or MTNB?

Synergy CHC currently has a consensus target price of $10.00, suggesting a potential upside of 240.14%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts plainly believe Synergy CHC is more favorable than Matinas Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Matinas Biopharma	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the media favor SNYR or MTNB?

In the previous week, Synergy CHC had 10 more articles in the media than Matinas Biopharma. MarketBeat recorded 10 mentions for Synergy CHC and 0 mentions for Matinas Biopharma. Matinas Biopharma's average media sentiment score of 1.00 beat Synergy CHC's score of -0.02 indicating that Matinas Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Synergy CHC	Neutral
Matinas Biopharma	Positive

Summary

Synergy CHC beats Matinas Biopharma on 13 of the 15 factors compared between the two stocks.